292 related articles for article (PubMed ID: 25766252)
1. Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.
Kwan HY; Niu X; Dai W; Tong T; Chao X; Su T; Chan CL; Lee KC; Fu X; Yi H; Yu H; Li T; Tse AK; Fong WF; Pan SY; Lu A; Yu ZL
Sci Rep; 2015 Mar; 5():9114. PubMed ID: 25766252
[TBL] [Abstract][Full Text] [Related]
2. Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet.
Jeong MJ; Kim SR; Jung UJ
Nutr Res; 2019 Apr; 64():64-71. PubMed ID: 30802724
[TBL] [Abstract][Full Text] [Related]
3. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
[TBL] [Abstract][Full Text] [Related]
4. Schisandrin B inhibits LPS-induced inflammatory response in human umbilical vein endothelial cells by activating Nrf2.
Lin Q; Qin X; Shi M; Qin Z; Meng Y; Qin Z; Guo S
Int Immunopharmacol; 2017 Aug; 49():142-147. PubMed ID: 28577438
[TBL] [Abstract][Full Text] [Related]
5. Hepatoprotective Effects of Soybean Embryo by Enhancing Adiponectin-Mediated AMP-Activated Protein Kinase α Pathway in High-Fat and High-Cholesterol Diet-Induced Nonalcoholic Fatty Liver Disease.
Hong J; Kim S; Kim HS
J Med Food; 2016 Jun; 19(6):549-59. PubMed ID: 27266339
[TBL] [Abstract][Full Text] [Related]
6. The chloroform extract of Cyclocarya paliurus attenuates high-fat diet induced non-alcoholic hepatic steatosis in Sprague Dawley rats.
Lin Z; Wu ZF; Jiang CH; Zhang QW; Ouyang S; Che CT; Zhang J; Yin ZQ
Phytomedicine; 2016 Nov; 23(12):1475-1483. PubMed ID: 27765368
[TBL] [Abstract][Full Text] [Related]
7. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
8. Schisandrin B regulates lipid metabolism in subcutaneous adipocytes.
Kwan HY; Wu J; Su T; Chao XJ; Yu H; Liu B; Fu X; Tse AKW; Chan CL; Fong WF; Yu ZL
Sci Rep; 2017 Aug; 7(1):10266. PubMed ID: 28860616
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.
Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells.
Chu JH; Wang H; Ye Y; Chan PK; Pan SY; Fong WF; Yu ZL
World J Gastroenterol; 2011 May; 17(19):2379-88. PubMed ID: 21633637
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of Rubi Fructus extracts on hepatic steatosis development in high-fat diet-induced obese mice.
Nam MK; Choi HR; Cho JS; Cho SM; Ha KC; Kim TH; Ryu HY; Lee YI
Mol Med Rep; 2014 Oct; 10(4):1821-7. PubMed ID: 25050832
[TBL] [Abstract][Full Text] [Related]
12. Chokeberry attenuates the expression of genes related to de novo lipogenesis in the hepatocytes of mice with nonalcoholic fatty liver disease.
Park H; Liu Y; Kim HS; Shin JH
Nutr Res; 2016 Jan; 36(1):57-64. PubMed ID: 26773781
[TBL] [Abstract][Full Text] [Related]
13. Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice.
Wang CM; Yuan RS; Zhuang WY; Sun JH; Wu JY; Li H; Chen JG
Lipids Health Dis; 2016 Nov; 15(1):195. PubMed ID: 27852305
[TBL] [Abstract][Full Text] [Related]
14. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
15. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
16. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice.
Sun JH; Liu X; Cong LX; Li H; Zhang CY; Chen JG; Wang CM
Lipids Health Dis; 2017 Aug; 16(1):145. PubMed ID: 28764799
[TBL] [Abstract][Full Text] [Related]
18. Schisandrin B protects against angiotensin II-induced endotheliocyte deficits by targeting Keap1 and activating Nrf2 pathway.
Han J; Shi X; Zheng Z; Zhang B; Shi F; Jiang L; Xu J
Drug Des Devel Ther; 2018; 12():3985-3997. PubMed ID: 30538426
[TBL] [Abstract][Full Text] [Related]
19. Sedative and hypnotic effects of Schisandrin B through increasing GABA/Glu ratio and upregulating the expression of GABA
Li N; Liu J; Wang M; Yu Z; Zhu K; Gao J; Wang C; Sun J; Chen J; Li H
Biomed Pharmacother; 2018 Jul; 103():509-516. PubMed ID: 29677536
[TBL] [Abstract][Full Text] [Related]
20. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
